A biocompatible biodegradable bone cement that can fill bone cavities, support soft tissue and deliver drugs has been developed using polylactide-co-glycolide. FDA has approved this material for parenteral use. Phase I showed that the cement retains its integrity in vivo and appears to promote bone regrowth. Microbiological studies indicated that the cement could be used for delivery of antibiotics. Erythromycin incorporated into the cement is released for more than one month. The Phase II proposal extends the Phase I study into standardizing the procedures and characterizing the reproducibility and degradation rates. The investigator plans to use the cement to deliver the antibiotic tobromycin and to determine its ability to promote healing in the long bones of sheep.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AR042800-02A2
Application #
2795875
Study Section
Special Emphasis Panel (ZRG4-SSS-5 (11))
Program Officer
Panagis, James S
Project Start
1995-09-10
Project End
2001-02-28
Budget Start
1999-03-05
Budget End
2000-02-29
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Biotek, Inc.
Department
Type
DUNS #
City
Woburn
State
MA
Country
United States
Zip Code
01801